Triple negative breast cancer

• Early detection of triple negative breast cancer relapse (CUPCAKE) Not authorised
  2022-501562-22-00 4 "Triple-negative breast cancer (TNBC) patients at high risk o"
• CELL-BASED IMMUNOTHERAPY FOR TREATMENT OF TRIPLE NEGATIVE BREAST CANCER STAGES II AND III Not authorised
  2023-506019-16-01 7 "TRIPLE NEGATIVE BREAST CANCER"
• CELL-BASED IMMUNOTHERAPY FOR TREATMENT OF TRIPLE NEGATIVE BREAST CANCER STAGES II AND III Pending
  2023-506019-16-03 7 "TRIPLE NEGATIVE BREAST CANCER"
• NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan+pembrolizumab vs. SoC chemotherapy in clinical st … Pending
  2024-516734-35-00 5 "triple-negative early breast cancer"
• Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors Pending
  2025-523232-39-00 1 "Advanced Solid Tumors"
• Adjuvant Pembrolizumab in patients with early-stage triple negative breast cancer with residual disease after treatment with chemotherapy an … Pending
  2025-524229-41-00 5
• A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications Recruiting
  2023-506227-29-00 3 2024-08-30 "locally advanced or metastatic solid tumors"
• A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and s … Recruiting
  2025-521702-18-00 1 2026-05-21 "Locally advanced unresectable or metastatic colorectal cance"
• Repurposing statins as adjuvants for cancer patients receiving therapy with immune checkpoint inhibitors: the STARK trial Recruiting
  2024-518500-47-00 4 2026-04-07 "Non Small Cell Lung Cancer (NSCLC)"
• A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity … Recruiting
  2025-523165-19-00 1 2026-02-10 "Advanced, metastatic or unresectable solid tumors"
• Early detection of triple negative breast cancer relapse (CUPCAKE) Recruiting
  2022-501562-22-01 4 2026-01-05 "Triple-negative breast cancer (TNBC) patients at high risk o"
• A clinical study of patritumab deruxtecan in people with breast cancer Recruiting
  2024-514376-40-00 4 2025-10-15 "High Risk Early-Stage Triple Negative Breast Cancer (TNBC) o"
• Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in pati … Recruiting
  2023-510356-23-00 1 2025-07-18 "Locally advanced or metastatic unresectable colorectal cance"
• Treatment of advanced or metastatic triple negative breast cancer with tumor infiltrating lymphocytes (TILs). Recruiting
  2024-511915-21-01 1 2025-05-05 "advanced or metastasic triple-negative breast cancer"
• Capecitabine plus pembrolizumab in patients with triple negative breast cancer after chemoimmunotherapy and surgery Recruiting
  2023-505291-30-01 4 2025-03-06 "Triple Negative Breast Cancer with residual disease after ne"
• Phase II study to test whether a combination of three drugs—atezolizumab, vinorelbine, and weekly cyclophosphamide—can activate T-cells in p … Recruiting
  2024-514031-20-00 4 2025-02-24 "Inoperable locally advanced or metastatic TNBC patients, pre"
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting
  2024-512279-10-00 5 2024-11-25 "Triple Negative Breast Cancer"
• An open-label, phase I/II multicenter clinical trial of NECVAX-NEO1 as add-on to first-line neoadjuvant anti-PD-1 monoclonal antibody therap … Recruiting
  2024-512520-11-00 9 2024-11-19 "Triple negative breast cancer (TNBC)"
• Immunotherapy and chemotherapy treatment or no treatment guided by the level of tumour-infiltrating cells in resected early-stage triple-neg … Recruiting
  2023-504620-26-00 4 2024-11-04
• NeoAdjuvant study comparing sacituzumab govitecan versus sacituzumab govitecan+pembrolizumab treatment in low-risk, triple-negative early br … Recruiting
  2023-508787-29-00 4 2024-10-10 "Triple-negative early breast cancer with low risk for recurr"
• Study to compare the activation of the immune system depending on the chemotherapy scheme used together with PEMBROLIZUM (immunotherapy) in … Recruiting
  2023-507008-30-00 4 2024-04-17 "High risk (TILs-positive) HR-/HER2- (triple negative) breast"
• Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors Recruiting
  2023-506604-18-00 1 2024-02-14
• Use of Imatinib to convert triple negative breast cancer into ER-positive breast cancer - I-CONIC Recruiting
  2024-511141-19-00 4 2022-08-22 "Primary breast cancer"
• Study of Zelenectide Pevedotin in Participants with Advanced Breast Cancer Recruitment ended
  2024-517868-33-00 4 2025-06-12 "NECTIN4 Amplified Advanced Breast Cancer"

Showing 1–24 of 60 trials